Mohamed Dauda, MD
Family Medicine · Baltimore, MDNPI 1124210026
Payments from drug & device makers
Across 102 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$754
- Neurocrine Biosciences, Inc.$552
- Exact Sciences$246
- Bayer$231
- Lexicon Pharmaceuticals, Inc.$186
- Dynavax Technologies Corporation$163
- plus $700 from 15 others
What the payments were for
- Food & beverage$2,833100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $754 |
| Neurocrine Biosciences, Inc. | 24 | $552 |
| Exact Sciences | 10 | $246 |
| Bayer | 12 | $231 |
| Lexicon Pharmaceuticals, Inc. | 5 | $186 |
| Dynavax Technologies Corporation | 5 | $163 |
| Dexcom, Inc. | 5 | $131 |
| Scilex Pharmaceuticals Inc. | 1 | $125 |
| Novartis | 1 | $73 |
| Novo Nordisk | 3 | $60 |
| Johnson & Johnson | 3 | $56 |
| Pfizer | 2 | $53 |
| Medtronic(2 entities) | 2 | $39 |
| Merck | 3 | $37 |
| Lilly USA, LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Viiv Healthcare Company | 1 | $16 |
| GSK | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$342
- Inpefa$125
- ELYXYB - CELECOXIB$125
- BREZTRI$122
- Heplisav-B$101
How this compares
$2,833 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $180,499 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 22 | $96,830 |
| OzempicSemaglutide | 57 | $79,952 |
| EliquisApixaban | 50 | $60,255 |
| JardianceEmpagliflozin | 50 | $40,550 |
| TrulicityDulaglutide | 21 | $35,254 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $34,211 |
| FarxigaDapagliflozin Propanediol | 30 | $32,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,326 |
| XareltoRivaroxaban | 24 | $20,898 |
| JanuviaSitagliptin Phosphate | 21 | $20,103 |
| TradjentaLinagliptin | 11 | $15,283 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,065 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,278 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $8,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $552 | $180,49920 claims |
| Novo NordiskOzempic, Levemir | $60 | $81,11769 claims |
| PfizerEliquis | $53 | $60,25550 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $35,39149 claims |
| Lilly USA, LLCTrulicity | $27 | $35,25421 claims |
| Viiv Healthcare CompanyDovato | $16 | $34,21112 claims |
| AstraZenecaFarxiga | $754 | $32,05330 claims |
| Johnson & JohnsonXarelto | $56 | $20,89824 claims |
| MerckJanuvia | $37 | $20,10321 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $125 | $2,10522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Baltimore
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Daljeet SalujaBaltimore$63K
- Fernando PorterBaltimore$54K
- Richard ColganBaltimore$31K
- Stacy GarrettBaltimore$20K
- Nishant ShahBaltimore$17K
- Diaa MikhailBaltimore$15K
- Yaniv BergerBaltimore$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.